Abstract
Congenital heart defects (CHDs) have specific hemodynamics due to volume and pressure overloads of the heart chambers. Such hemodynamic disorders contribute to the development of hypertrophy and myocardial fibrosis, heart failure, damage and death of cardiomyocytes. Measurement of biomarker levels helps predict the development of these pathological conditions and provides information on the severity of the lesion. Information on the use of cardiac biomarkers in pediatric practice is limited, compared to the extensive data on the practical use of cardiac biomarkers in adult patients, primarily with coronary artery disease. We reviewed the current publications on the use of cardiac biomarkers in pediatric patients with CHDs, focusing on troponin as a biomarker of myocardial injury and B-type natriuretic peptide (BNP) as a biomarker of heart failure.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
